Piramal Pharma Limited targets full Yapan ownership via 26% call
Key highlights
- Piramal Pharma holds 74% of Yapan and has exercised an option for the remaining 26%.
- The proposed purchase would raise Piramal Pharma’s Yapan ownership from 74% to 100% on completion.
- Yapan provides vaccines and biologics CDMO services, including Phase I and Phase II GMP manufacturing.
- The acquisition price and effective date of the 26% share transfer have not been finalised.
powered by IRIS

Piramal Pharma Limited has approved exercise of a call option to buy Yapan Bio Private Limited’s remaining 26% equity stake, which would raise its holding from 74% to 100% upon completion, although the acquisition consideration and effective share-transfer date have not been finalised.
Know Piramal Pharma inside out
Results, valuation, peers and who's buying, in one view.
What has Piramal Pharma announced about Yapan?
Piramal Pharma has approved the exercise of its call option to acquire the balance 26% equity stake in Yapan from Yapan’s existing shareholders. The approval came from the Administrative Committee of Piramal Pharma’s Board of Directors, acting under authority delegated by the board, and the company describes the purchase as the Proposed Transaction.
The 26% call-option exercise does not mean the share transfer has already occurred. Piramal Pharma says it is in discussions with Yapan’s shareholders on matters needed to consummate the Proposed Transaction, meaning the disclosure covers a board-authorised step toward acquisition rather than a completed ownership change.
The disclosure was made under Regulation 30 of the Securities and Exchange Board of India, or SEBI, Listing Obligations and Disclosure Requirements Regulations, 2015. Piramal Pharma said it would make further disclosures after definitive documentation is executed and the Proposed Transaction is completed, including details required under Regulation 30.
How would the 26% Yapan purchase change ownership?
The proposed acquisition would increase Piramal Pharma’s shareholding in Yapan from 74% to 100%, making Yapan a wholly owned subsidiary if the transaction completes. The stated change is a 26-percentage-point increase in Piramal Pharma’s equity interest, rather than the acquisition of a business in which it had no existing holding.
At the current 74% level, Yapan is already identified in the announcement as a subsidiary of Piramal Pharma. At the expected 100% level, it would become a wholly owned subsidiary, which is the specific corporate-status change set out in the filing.
The filing does not disclose how the existing 74% stake was acquired, the identities of shareholders selling the 26%, or the number of Yapan shares involved. It also provides no valuation for either the 26% stake or Yapan as a whole, limiting the disclosed comparison to the 74%, 26% and expected 100% equity positions.
What does Yapan do for Piramal Pharma?
Yapan is a contract development and manufacturing organisation, or CDMO, specialising in process development, characterisation and Phase I and Phase II Good Manufacturing Practice, or GMP, manufacturing services for vaccines and biologics. The 26% transaction concerns this vaccines-and-biologics-focused subsidiary rather than a retail pharmaceutical product operation described in the filing.
The announcement identifies three Yapan service areas: process development, characterisation, and Phase I and Phase II GMP manufacturing. Phase I and Phase II are the stages named in the filing, while GMP is the manufacturing standard specified by Piramal Pharma; the disclosure provides no capacity, customer, revenue, facility or product-specific figures for these activities.
For Piramal Pharma, a move from 74% to the expected 100% would place all equity in this CDMO subsidiary under its ownership, subject to completion of the 26% purchase. The filing does not state operational integration plans, management changes at Yapan, or a financial target linked to full ownership, so those outcomes cannot be inferred from the approval alone.
Got a follow-up? Ask IRIS
What terms remain unresolved in the Yapan transaction?
The acquisition consideration and effective date of transfer of the 26% shares are yet to be finalised. These are the two explicitly unresolved transaction terms identified by Piramal Pharma, so the filing does not establish either the amount to be paid or the date on which the expected move from 74% to 100% would take effect.
Piramal Pharma says it is discussing matters necessary to consummate the Proposed Transaction with Yapan’s shareholders. It has not stated a closing deadline, payment structure, whether consideration will be paid in cash or another form, or conditions that must be met before transfer of the 26% stake can be completed.
The company said appropriate disclosures will follow upon execution of definitive documentation and completion. In describing those future disclosures, Piramal Pharma cited Regulation 30 and SEBI Master Circular No. HO/49/14/14(7)2025CFD-POD2/I/3762/2026, dated January 30, 2026, but the current announcement supplies no signed-document date or completion date.
Why is the call option approval not yet a completed acquisition?
The call option approval is not a completed acquisition because Piramal Pharma says the final terms, including consideration and the effective transfer date, remain unsettled. The expected 100% shareholding is expressly linked to completion of the Proposed Transaction, while the currently disclosed ownership remains 74%.
The Administrative Committee’s approval, made under board-delegated authority, authorises exercise of the option for the remaining 26%. Piramal Pharma also says definitive documentation must be executed and the transaction completed before it issues further Regulation 30 details, distinguishing the authorisation from legal and operational completion.
The filing does not disclose a termination scenario, amendment mechanism, funding source or accounting effect for the 26% acquisition. The disclosed facts therefore establish an intended 100% ownership outcome, but not the final economics or timetable required to reach that outcome.
Conclusion
The call-option exercise sets out Piramal Pharma’s intended move from a 74% stake to complete ownership of a vaccines-and-biologics CDMO subsidiary. Yapan’s disclosed work covers process development, characterisation and Phase I and Phase II GMP manufacturing, while the consideration for the remaining 26% has not been disclosed.
The next item to watch is execution of definitive documentation and completion of the Proposed Transaction. Piramal Pharma has said that a subsequent Regulation 30 disclosure will provide the final acquisition consideration, effective transfer date for the 26% stake and confirmation of Yapan’s status as a wholly owned subsidiary.


